Search - tctmd.com

Displaying 421 - 440 of 577

Sort: Relevancy | Date

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

News Daily News

Modified Risk Score for ED Chest Pain Patients Reduces Hospital Stays, Lowers Costs

Michael O'Riordan

October 03, 2017

News Daily News

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

Michael O'Riordan

September 29, 2017

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Daily News

Ischemic Heart Disease the Leading Cause of Death Globally

Michael O'Riordan

September 19, 2017

News Daily News

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Michael O'Riordan

September 15, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

Supplemental Oxygen Provides No Benefit to Patients With Suspected MI: DETO2X-AMI

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Conference News ESC 2017

Mortality After Acute MI Halved Over Two Decades in Switzerland, With Greatest Gains by Women

Michael O'Riordan

August 26, 2017

News Daily News

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Michael O'Riordan

August 14, 2017

News Daily News

Reusing the Radial: Repeat Transradial Access Safe and Feasible, Even Within 24 Hours

Michael O'Riordan

August 09, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

Advertisement

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Modified Risk Score for ED Chest Pain Patients Reduces Hospital Stays, Lowers Costs

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

New Performance and Quality Metrics for STEMI and NSTEMI Care

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Ischemic Heart Disease the Leading Cause of Death Globally

Patients in PCI Trials Vary Around the World, With Women Still Underrepresented

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Supplemental Oxygen Provides No Benefit to Patients With Suspected MI: DETO2X-AMI

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

ESC Updates Guidelines for Treating STEMI Patients

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Mortality After Acute MI Halved Over Two Decades in Switzerland, With Greatest Gains by Women

Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests

Reusing the Radial: Repeat Transradial Access Safe and Feasible, Even Within 24 Hours

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content